Join Growin Stock Community!

Jade biosciences, inc.JBIO.US Overview

US StockHealthcare
(No presentation for JBIO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

JBIO AI Insights

JBIO Overall Performance

JBIO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

JBIO Recent Performance

-3.98%

Jade biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

JBIO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

JBIO Key Information

JBIO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

JBIO Profile

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

Price of JBIO

JBIO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

JBIO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.00
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is JBIO's latest earnings report released?

    The most recent financial report for Jade biosciences, inc. (JBIO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JBIO's short-term business performance and financial health. For the latest updates on JBIO's earnings releases, visit this page regularly.

  • How much cash does JBIO have?

    At the end of the period, Jade biosciences, inc. (JBIO) held Total Cash and Cash Equivalents of 50.11M, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is JBIO's EPS continuing to grow?

    According to the past four quarterly reports, Jade biosciences, inc. (JBIO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.48. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of JBIO?

    Jade biosciences, inc. (JBIO)'s Free Cash Flow (FCF) for the period is -22.18M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 159.46% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of JBIO?

    The latest valuation data shows Jade biosciences, inc. (JBIO) has a Price-To-Earnings (PE) ratio of -7.54 and a Price/Earnings-To-Growth (PEG) ratio of 0.08. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.